(Q34568205)

3 August 2017

4 references

18 November 2019

27 November 2019

21 December 2019

1 February 2021

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? (English)

1 reference

Protein C, inactivator of coagulation factors Va and VIIIa

3 August 2017

0 references

1 reference

18 November 2019

1 reference

27 November 2019

1 reference

21 December 2019

1 reference

1 February 2021

1 reference

Jan O Friedrich

1

1 reference

3 August 2017

Neill K J Adhikari

series ordinal

2

1 reference

3 August 2017

Maureen O Meade

series ordinal

3

1 reference

3 August 2017

language of work or name

1 reference

2 June 2006

5 references

3 August 2017

18 November 2019

27 November 2019

21 December 2019

1 February 2021

5 references

3 August 2017

18 November 2019

27 November 2019

21 December 2019

1 February 2021

10

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

145

1 reference

Intensive insulin therapy in the medical ICU.

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Application of a population-based severity scoring system to individual patients results in frequent misclassification

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Randomized trials stopped early for benefit: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Measuring inconsistency in meta-analyses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Assessing the use of activated protein C in the treatment of severe sepsis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Risks and benefits of activated protein C treatment for severe sepsis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Intensive insulin therapy in critically ill patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Efficacy and safety of recombinant human activated protein C for severe sepsis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Subgroup analysis and other (mis)uses of baseline data in clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

APACHE II: a severity of disease classification system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Practical problems in interim analyses, with particular regard to estimation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

A consumer's guide to subgroup analyses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Activated protein C: do more survive?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Monitoring of large randomised clinical trials: a new approach with Bayesian methods

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Drotrecogin Alfa (Activated) in Severe Sepsis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550958

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

9 December 2018

1 reference

12 December 2020

Prescribing indications based on successful clinical trials in sepsis: a difficult exercise

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1186/CC4947

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference